Login
Registrati
Reimposta password
Pubblica & Distribuisci
Soluzioni Editoriali
Soluzioni di Distribuzione
Temi
Architettura e design
Arti
Business e Economia
Chimica
Chimica industriale
Farmacia
Filosofia
Fisica
Geoscienze
Ingegneria
Interesse generale
Legge
Letteratura
Linguistica e semiotica
Matematica
Medicina
Musica
Scienze bibliotecarie e dell'informazione, studi library
Scienze dei materiali
Scienze della vita
Scienze informatiche
Scienze sociali
Sport e tempo libero
Storia
Studi classici e del Vicino Oriente antico
Studi culturali
Studi ebraici
Teologia e religione
Pubblicazioni
Riviste
Libri
Atti
Editori
Blog
Contatti
Cerca
EUR
USD
GBP
Italiano
English
Deutsch
Polski
Español
Français
Italiano
Carrello
Home
Riviste
The EuroBiotech Journal
Volume 3 (2019): Numero 1 (January 2019)
Accesso libero
Low-frequency ultrasound can drive the transport of nanoparticles and molecules in polymer gels for biotechnology applications
Donald K. Martin
Donald K. Martin
| 25 gen 2019
The EuroBiotech Journal
Volume 3 (2019): Numero 1 (January 2019)
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Sommario
Articolo
Immagini e tabelle
Bibliografia
Autori
Articoli in questo Numero
Anteprima
PDF
Cita
CONDIVIDI
Article Category:
Research Article
Pubblicato online:
25 gen 2019
Pagine:
1 - 9
DOI:
https://doi.org/10.2478/ebtj-2019-0001
Parole chiave
Gold nanoparticles
,
agarose gel
,
drug delivery
,
low-frequency ultrasound
© 2019 Donald K. Martin, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Apparatus used to measure the transport of tracer gold nanoparticles that as stimulated by low-frequency ultrasound. The block diagram of the components is drawn in panel A, and the actual gels+transducer is shown in panel B. The light path is illustrated with the dotted line, and was aimed to pass through the “receiver-gel” at a distance marked x below the interface with the “tracer-gel”. The numbers in panels A and B refer to the same components. (1=ultrasonic transducer, 2=”tracer-gel”, 3=”receiver-gel”, 4=glass microscope slide, 5=signal generator, 6=HeNe laser, 7=photodiode, 8=computer).
Figure 2
Measurement of transmittance of the “receiver-gel” at x=1mm depth from the interface with the “tracer-gel” that contained the gold nanoparticles.
Figure 3
Measurement of transmittance of the “receiver-gel” at x=2mm depth from the interface with the “tracer-gel” that contained the gold nanoparticles.
Figure 4
SEM image of the “receiver-gel” from the diffusion experiment shown in Fig. 1. For the purposes of the SEM imaging the gel was dehydrated. The electron-dense particles (light grey colour) are at the surface of the dehydrated gel. The arrows point to particles that are most likely to be gold, with the alrger particles most likely to be crystals of chemicals used in the buffer solutions (see text for explanation).
Figure 5
SEM/EDS analysis of the smaller particles observed in the dehydrated gels shown in Figure 4. The EDS analysis in panel B is of the particle imaged by SEM in panel A. The analysis shows that the composition of the particle in panel A is gold.
Figure 6
Measurement of transmittance of the “receiver-gel” at x=1mm depth from the interface with the “tracer-gel” that did not contain any gold nanoparticles.
Figure 7A
Masson-stained section of a posterior area of a rabbit eye into which bevacizumab was delivered from the “tracer-gel”. The sclera is stained bright blue and the retina, epithelia and muscle stained crimson. The retina and choroid have separated from the sclera.
Figure 7B
Masson-stained section of the limbal region of a rabbit eye into which bevacizumab was delivered from the “tracer-gel”. The sclera and cornea are stained bright blue and the retina, epithelia and muscle stained crimson. The retina and choroid have separated from the sclera.
Figure 8
Sections of the retina and sclera around the posterior pole of the rabbit eyes. In all panels the retina is marked “ret” and the sclera is marked “scl”. (A) bevacizumab, free in gel (rabbit 1, left eye), (B) bevacizumab, in liposomes (rabbit 1, right eye), (C) negative control (rabbit 2, left eye), (D) ranibizumab, free in gel (rabbit 2, right eye), (E) verteporfin, direct injection into vitreous chamber (rabbit 3, left eye), (F) verteporfin, in liposomes (rabbit 3, right eye).
Anteprima